Fig. 2

Recurrent gains are the underlying mechanism responsible for MAZ overexpression. a, b The percentage of MAZ with gains in the PCa samples from TCGA-PRAD and GSE74685. c, d The average expression level of MAZ in PCa tissues with gains exceeded those with diploid in TCGA-PRAD and GSE74685 samples. Each bar stands for median values ± quartile values. *P < 0.05. e The percentage of MAZ with gains in our PCa samples. f The average expression level of MAZ in PCa samples with gains and metastasis bone tissues of PCa samples with gains exceeded those samples with diploid gains. Each bar stands for median values ± quartile values. g Percentages and numbers of MAZ samples with gains in PCa samples with distinct bone metastasis status and in metastasis bone samples of PCa. h Kaplan-Meyer analysis of our PCa patients bone metastasis-free survival between the MAZ-overexpression (n = 122) and MAZ-downexpression (n = 121) group (Log-rank Test). i Kaplan-Meyer analysis of our PCa patients overall survival between the MAZ-overexpression (n = 122) and MAZ-downexpression (n = 121) group (Log-rank Test)